LATP

LATP:

Two leading products (LTP-03, and LTP-0401) are in early pre-clinical stage. The efficacy and toxicity were confirmed in rodent studies. IND-enabling studies of LTP-03 has been in progress.

  • Triple agonist of GLP-1, GIP and glucagon with prolonged half-life
  • Balanced activation on GLP-1R, GIPR and GCGR
  • No significant suppression of food intake in DIO mouse model
  • High homogeneity and stability
  • Low immunogenicity: all natural amino acid and no chemical modifications
  • Minimized CVD risk due to controlled GCGR activation
  • Easy adapted to combination of other hormones for broad indication in obesity, blood glucose control, NAFLD and cardiovascular disease
  • A long-acting therapeutic protein to manage chronic pain
  • High yield, homogeneity and stability
  • Low immunogenicity: all natural amino acid and no chemical modification
  • Non-opioid receptor relevant
  • Effectively alleviates pain in animal models
Scroll to Top